Just In
- 3 hrs ago Golden Rules To Follow For Happy Marriage For A Long Lasting Relationship
- 4 hrs ago Gajalakshmi Rajyog In Aries 2024: Lucky Zodiac Signs Who Will Get Financial Benefits
- 7 hrs ago Met Gala 2024: Date, Theme, Venue, Guest List, All You Need To Know About The Fashion Event
- 14 hrs ago Summer Fashion: Your Bollywood Style White Outfits Guide To Keep It Cool And Chic
Don't Miss
- Movies Pukaar Dil Se Dil Tak Promo: Sayli Salunkhe Impresses In First Video Of Sony TV Show, Details About Her Role
- Sports Who Won Yesterday's IPL Match 34? LSG vs CSK, IPL 2024 on April 19: KL Rahul Stellar Batting Show Decimate Chennai Bowling
- Finance Rs 17/Share Dividend: Record Date On April 26; Buy The ICICI Group Stock To Be Eligible?
- News Chinese President Xi Jinping Orders Biggest Military Reorganisation Since 2015
- Education Exam Pressure Does Not Exist; Studying Punctually is Crucial; Says Aditi, the PSEB 2024 Topper
- Automobiles Suzuki Swift Hatchback Scores 4 Star Safety Rating At JNCAP – ADAS, New Engine & More
- Technology Dell Introduces AI-Powered Laptops and Mobile Workstations for Enterprises in India
- Travel Journey From Delhi To Ooty: Top Transport Options And Attractions
COVID-19: Antibodies 1000 Times Better At Neutralising SARS-Cov-2 Developed From Alpacas
According to a recent report, researchers at Germany's Max Planck Institute (MPI) for Biophysical Chemistry have developed antibodies that are highly potent and stable and can effectively block SARS CoV-2, the virus which causes COVID-19 [1].
The antibodies were developed from the blood of alpacas, a species of South American camelid mammal that looks like a llama. The scientists claim the mini-antibodies are effective against the new COVID variants and are up to 1000 times better than previously developed mini-antibodies [2]. Moreover, the researchers were able to perfect the mini-antibodies to such an extent that they are highly stable and heat-resistant [3].
COVID-19 Antibodies Developed From Alpaca Blood: Everything You Need To Know
As India is bracing itself for the possible advent of the COVID-19 third wave, Middle East has reported the fourth wave, triggered by the delta-variant [4]. Amidst this comes the study findings of alpaca blood antibodies, which could become a promising agent for treating COVID-19.
Efforts to design a safe vaccine for COVID-19 are moving forward. Yet, experts agree that it's likely to be a year, at least, before immunisation is ready. In the meantime, European scientists are exploring ingenious ways, such as the help of alpacas, using the latest techniques in molecular manipulation to repair coronavirus-induced lung damage or block the virus before it wreaks havoc in the body [5].
How are antibodies developed? How are they different from vaccines?
Vaccines are given to people when they are well, prompting them to develop their antibodies, whereas antibody therapy is administered when an infection has taken hold and a patient is struggling to develop or function through their own immune response [6].
Returning To Work Post-COVID? What To Do And What To Avoid
As recent research findings suggest, monoclonal antibodies (mAbs) (antibodies that are identical clones of one another) have emerged over the past few decades as effective therapies for various medical conditions, including cancers and autoimmune disorders [7].
And they are also considered a major medical tool to fight severe viral infections, such as COVID-19, although, to date, only one mAb has been approved for this purpose.
Why were alpacas chosen for the study?
Three alpaca mares Britta, Nora and Xenia, provided the blueprints for the COVID-19 nanobodies. The research team is focusing on mice, rhesus macaques and alpacas, and alpacas were shown to have a (possible) important role in producing particularly interesting antibody fragments, known as 'single domain', antibodies, which allow for fast antibody discovery and large-scale antibody production [8].
Mining the alpaca antibody repertoire is currently underway. Over the next few weeks, the researchers will be testing the neutralising activity of the produced antibodies against SARS-CoV-2.
The researchers had inoculated their alpacas with part of the spike protein of the first known SARS-CoV-2 virus. Their immune systems also produced antibodies active against the alpha, beta, gamma and delta variants of the virus.
"If our nanobodies prove to be too ineffective against a future variant, we can re-immunise the alpacas. Since they have already been vaccinated against the virus, they would very quickly adapt their antibodies to the new variants," the scientists added.
COVID-19: Post-Covid Symptoms Like Breathlessness, Headaches Reported In Children
What does this mean for COVID-19 management?
As nanobodies are easier to produce in comparison to other treatment methods due to the low cost of production, they can be produced inexpensively and quickly in large quantities, meeting the global need for COVID-19 drugs. Even the simplest mini-antibodies from the Göttingen researchers bind up to 1000 times more strongly to the spike protein than previously developed nanobodies against COVID-19 [9].
These antibodies bind very well to the mutant receptor-binding domains of the alpha, beta, gamma and delta strains. "Our simple nanobodies may be suitable for being inhaled to contain the virus in the respiratory tract. Also, because they are very small, they can easily penetrate tissues and prevent the virus from spreading further directly at the site of infection," said one of the scientists [10].
On A Final Note...
The study added that the COVID-19 antibodies are being prepared for clinical trials.
- pregnancy parentingMysterious Pneumonia Outbreak In China: What Are The Long-Term Effects Of Pneumonia In Children?
- healthCan You Get Back COVID-Related Loss Of Sense Of Smell And Taste (Parosmia)? Looks Like You Can!
- healthDid Covid-10 Vaccination Increase Risk Of Sudden Deaths In Young Adults? ICMR Finds This..
- wellnessDelhi Air Pollution, Air Quality Very Poor: Do Covid Masks Help Reduce Pollution Side Effects?
- healthNobel Prize 2023: Scientists Behind The COVID-19 mRNA Vaccines Wins
- healthWhat Is Disease X? 20 Times More Deadlier Than Covid 19; Can Cause 50 Million Deaths, Does It Have Vaccine?
- healthCOVID-19 Vaccines and Heart Attacks: New Studies Show Different Results; What Are They?
- healthDo You Pick Your Nose? Stop! It Can Increase COVID Risk
- healthEris Variant: WHO Alarms New Covid Wave; Should India Be Concerned About This Pandemic
- healthVitamin D Deficiency Linked With Increased Risk Of Long COVID
- healthCOVID Surge In India: Do You Need A COVID-19 Booster Shot?
- healthCOVID-19: IMA Cites 3 Reasons Behind Recent Surge In Covid-19 Cases: What Are They?